- Cover Page rev 09/24 (pdf)
- Section A: Purpose rev 04/24 (pdf)
- Section B: Maximum Daily Dose Summary rev 09/24 (pdf)
- Section C: Required Laboratory & Exam Summary rev 07/23 (pdf)
- Section D: Outpatient Documentation Requirement rev 11/15 (pdf)
- Section E: Inpatient Documentation Requirements rev 05/19 (pdf)
- Section F: Alzheimer's Agents rev 08/24 (pdf)
- Section G: Anti-anxiety Medications rev 10/19 (pdf)
- Section H: Anti-depressants rev 08/20 (pdf)
- Section I: Atypical Antipsychotics rev 12/20 (pdf)
- Section J: Conventional Antipsychotics rev 11/21 (pdf)
- Section K: Agents to Consider for Prevention and Treatment of Antipsychotic Induced Metabolic Syndrome 9/24 (pdf)
- Section L: Agents for Medication Induced Movement DO rev 02/22 (pdf)
- Section M: Psychostimulant rev 08/23 (pdf)
- Section N: Mood Stabilizers rev 10/23 (pdf)
- Section O: Sedative-Hypnotics Agents rev 12/19 (pdf)
- Section P: Guideline for Prescribing Controlled Psychotropics rev 10/22 (pdf)
- Section Q: Alpha Agonists rev 07/23 (pdf)
- Section R: Alcohol Use Treatment rev 11/24 (pdf)
- Section S: Agents Used to Treat Opioid Use Disorder rev 05/22 (pdf)
- Section T: Outpatient Documentation Requirements for MAT rev 04/22 (pdf)
